{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:13Z","timestamp":1793502913250,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a 6-month prospective observational study on postmenopausal women with severe OP receiving treatment with romosozumab either alone (in patients na\u00efve to treatment) or in combination with ongoing long-term denosumab (&amp;gt;2\u00a0years) or continuing ongoing denosumab alone (&amp;gt;2\u00a0years). We collected serum samples for bone turnover markers, bone modulators, and calcium phosphate metabolism at baseline, month 3 and month 6. BMD was assessed at baseline and after 6\u00a0months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-two postmenopausal women with OP were included in the study. Nineteen received romosozumab alone, 11 received romosozumab combined to ongoing denosumab, and 22 continued denosumab alone. BMD increased significantly at all sites at 6\u00a0months of follow-up in the romosozumab alone group (femoral neck +8.1%, total hip +6.8%, and lumbar spine +7.9%). In contrast, BMD increased significantly only at lumbar spine in the combination group (+7.2%) and in the denosumab group (+1.5%). P1nP increased significantly in romosozumab groups at month 3 (+70.4% in romosozumab alone group and\u2009+99.1% in combination group). Sclerostin levels increased steeply in both romosozumab groups, and Dkk1 did not change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Romosozumab added to ongoing denosumab resulted in an increase in P1nP and lumbar spine BMD, but not in femoral neck BMD. For patients on denosumab, using romosozumab as an additional treatment appeared to be useful in terms of bone formation markers and spine BMD vs denosumab alone. Further randomized controlled trials, possibly powered to fracture outcomes, are needed to confirm our results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jbmrpl\/ziae016","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T22:18:01Z","timestamp":1707344281000},"source":"Crossref","is-referenced-by-count":44,"title":["Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study"],"prefix":"10.1093","volume":"8","author":[{"given":"Giovanni","family":"Adami","sequence":"first","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pedrollo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Braga","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pasetto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pollastri","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Benini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit , Department of Medicine, , Verona, 37134 , Italy"},{"name":"University of Verona , Department of Medicine, , Verona, 37134 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024032800170076700_ref1","doi-asserted-by":"crossref","first-page":"1759720X2210835","DOI":"10.1177\/1759720X221083541","article-title":"Osteoporosis in 10 years time: a glimpse into the future of osteoporosis","volume":"14","author":"Adami","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"2024032800170076700_ref2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA Osteoporosis Study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024032800170076700_ref3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jbmr.4243","article-title":"Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis","volume":"36","author":"Dempster","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024032800170076700_ref4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jbmr.3309","article-title":"Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA Study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024032800170076700_ref5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2\u2009months of romosozumab treatment: results from the FRAME Clinical Trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024032800170076700_ref6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4158\/EP-2019-0596","article-title":"Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture","volume":"26","author":"Cosman","year":"2020","journal-title":"Endocr Pract"},{"issue":"10117","key":"2024032800170076700_ref7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"2024032800170076700_ref8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/clinem\/dgad496","article-title":"Sequential therapy for the long-term treatment of postmenopausal osteoporosis","volume":"109","author":"Ramchand","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032800170076700_ref9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","article-title":"Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women","volume":"123","author":"Fassio","year":"2019","journal-title":"Bone"},{"key":"2024032800170076700_ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"9999","key":"2024032800170076700_ref11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10102","key":"2024032800170076700_ref12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"2024032800170076700_ref13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2024032800170076700_ref14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2024032800170076700_ref15","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12\u2009months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"6","key":"2024032800170076700_ref16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024032800170076700_ref17","first-page":"561","article-title":"Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description","volume":"28","author":"Adami","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2024032800170076700_ref18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-015-0009-2","article-title":"Assessment of fracture risk in a population of postmenopausal Italian women: a comparison of two different tools","volume":"97","author":"Bonaccorsi","year":"2015","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2024032800170076700_ref19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/09513590.2017.1407308","article-title":"Fracture risk assessment in postmenopausal women with diabetes: comparison between DeFRA and FRAX tools","volume":"34","author":"Bonaccorsi","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"11","key":"2024032800170076700_ref20","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s40618-023-02082-8","article-title":"A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS","volume":"46","author":"Adami","year":"2023","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"2024032800170076700_ref21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","article-title":"Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis","volume":"34","author":"Kashii","year":"2023","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024032800170076700_ref22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","article-title":"Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin","volume":"50","author":"Gatti","year":"2012","journal-title":"Bone"},{"issue":"11","key":"2024032800170076700_ref23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024032800170076700_ref24","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/jbmr.3175","article-title":"Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts","volume":"32","author":"Koide","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024032800170076700_ref25","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat Commun"},{"key":"2024032800170076700_ref26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone"},{"issue":"2","key":"2024032800170076700_ref27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"2024032800170076700_ref28","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","article-title":"Teriparatide and denosumab combination therapy and skeletal metabolism","volume":"27","author":"Idolazzi","year":"2016","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024032800170076700_ref29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jbmr.3091","article-title":"Coupling of bone resorption and formation in real time: new knowledge gained from human Haversian BMUs","volume":"32","author":"Lassen","year":"2017","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae016\/56617006\/ziae016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/8\/4\/ziae016\/57097054\/ziae016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/8\/4\/ziae016\/57097054\/ziae016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:17:33Z","timestamp":1711585053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae016\/7603162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,2,7]]},"article-number":"ziae016"}}